In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae

Yee Huang Ku, Yin Ching Chuang, Wen Liang Yu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background and Purpose: Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Methods: 104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips. Results: The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively. Conclusions: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.

Original languageEnglish
Pages (from-to)332-336
Number of pages5
JournalJournal of Microbiology, Immunology and Infection
Volume41
Issue number4
Publication statusPublished - Aug 2008

Fingerprint

Enterobacter cloacae
Serratia marcescens
Klebsiella pneumoniae
beta-Lactamases
Enterobacteriaceae
Taiwan
Disk Diffusion Antimicrobial Tests
Bacteria
tigecycline
In Vitro Techniques
Pharmaceutical Preparations

Keywords

  • Beta-lactamase resistance
  • Beta-lactamases
  • Enterobacteriaceae
  • Microbial sensitivity tests
  • Minocycline

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Immunology and Allergy
  • Infectious Diseases
  • Microbiology (medical)

Cite this

@article{c607b622cbde446792f7f4006f7367c2,
title = "In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae",
abstract = "Background and Purpose: Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Methods: 104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips. Results: The minimal tigecycline concentration at which 50{\%} of isolates were inhibited and minimal concentration at which 90{\%} of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively. Conclusions: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.",
keywords = "Beta-lactamase resistance, Beta-lactamases, Enterobacteriaceae, Microbial sensitivity tests, Minocycline",
author = "Ku, {Yee Huang} and Chuang, {Yin Ching} and Yu, {Wen Liang}",
year = "2008",
month = "8",
language = "English",
volume = "41",
pages = "332--336",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "4",

}

TY - JOUR

T1 - In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae

AU - Ku, Yee Huang

AU - Chuang, Yin Ching

AU - Yu, Wen Liang

PY - 2008/8

Y1 - 2008/8

N2 - Background and Purpose: Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Methods: 104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips. Results: The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively. Conclusions: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.

AB - Background and Purpose: Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. Methods: 104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips. Results: The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 μg/mL and 0.5 to 1.5 μg/mL, respectively. Conclusions: Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.

KW - Beta-lactamase resistance

KW - Beta-lactamases

KW - Enterobacteriaceae

KW - Microbial sensitivity tests

KW - Minocycline

UR - http://www.scopus.com/inward/record.url?scp=57649116090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649116090&partnerID=8YFLogxK

M3 - Article

C2 - 18787741

AN - SCOPUS:57649116090

VL - 41

SP - 332

EP - 336

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 4

ER -